Clinical Trial Update: Study of Talabostat and Pemetrexed vs. Pemetrexed in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy [Phase 3]

View source ↗

Summary

Phase 3 trial comparing talabostat plus pemetrexed versus pemetrexed alone in Stage IIIB/IV non-small cell lung cancer after platinum-based chemotherapy was ter…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Pemetrexed (pemetrexed)
• Talabostat (talabostat)

Snippet

Sponsor: Point Therapeutics | Conditions: Carcinoma, Non-Small-Cell Lung, Lung Cancer | Phase 3 | Status: TERMINATED